ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCTX vs CPHI // ALTMAN Z-SCORE & DEBT/EQUITY

BriaCell Therapeutics Corp. (NASDAQ) VS. China Pharma Holdings Inc. (NYSE) • 15-METRIC TALLY: BCTX 1 — CPHI 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCTX VS. CPHI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCTX CPHI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — -3.20% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -11.40% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — 0.32% — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -8.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 4/9 -3.00 CPHI /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 31.2 40.2 -8.96 CPHI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $28.9M $28.0M $939.9K BCTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCTX REV CPHI REV BCTX GROSS % CPHI GROSS % BCTX FCF CPHI FCF
FY 2025 $0 $4.1M — -3.2% -$28.2M $88.9K
FY 2024 $0 $4.5M — -43.8% -$24.6M -$444.5K
FY 2023 $0 $7.0M — — -$23.7M -$699.7K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCTX // BETA —
CPHI // BETA —